ArticleJournal of Cancer2019
Cyclin-Dependent Kinase Inhibitor 3 Promoted Cell Proliferation by Driving Cell Cycle from G1 to S Phase in Esophageal Squamous Cell Carcinoma.
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Identification of novel genes with enriched expression in human intermediate progenitors reveals a key role for CDKN3 in cortical development.Stem cell reports · 2026Article
- MiR-192-5p targets cell cycle regulation in diabetic kidney disease via cyclin-dependent kinase inhibitor 3.Non-coding RNA research · 2025Article
- Characterization of breast cancer tumors in older patients who show de novo resistance to endocrine therapy.Scientific reports · 2024Article
- Evolution of the Cdk4/6-Cdkn2 system in invertebrates.Genes to cells : devoted to molecular & cellular mechanisms · 2024Article
- Aryl hydrocarbon receptor dynamics in esophageal squamous cell carcinoma: From immune modulation to therapeutic opportunities.World journal of experimental medicine · 2024Review
- The role of Cyclin Dependent Kinase Inhibitor 3 (Heliyon · 2024Review
- High-Throughput Cellular Heterogeneity Analysis in Cell Migration at the Single-Cell Level.Small (Weinheim an der Bergstrasse, Germany) · 2023Article
- Identification of Potential Biomarkers Using Integrative Approach: A Case Study of ESCC.SN computer science · 2023Article
- Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer.International journal of general medicine · 2023Article
- ncRNAs-mediated high expression of TICRR promotes tumor cell proliferation and migration and is correlated with poor prognosis and tumor immune infiltration of hepatocellular carcinoma.Molecular therapy. Nucleic acids · 2022Article
- KLF7 promotes preadipocyte proliferation via activation of the Akt signaling pathway byActa biochimica et biophysica Sinica · 2022Article
- lncRNA TPT1‑AS1 knockdown inhibits liver cancer cell proliferation, migration and invasion.Molecular medicine reports · 2021Article
- Integrated transcriptomics explored the cancer-promoting genes CDKN3 in esophageal squamous cell cancer.Journal of cardiothoracic surgery · 2021Article
- Meta-Analysis of Esophageal Cancer Transcriptomes Using Independent Component Analysis.Frontiers in genetics · 2021Article
- Discovery of a novel HDACi structure that inhibits the proliferation of ovarian cancer cellsInternational journal of biological sciences · 2021Article
- CDKN3 promotes cell proliferation, invasion and migration by activating the AKT signaling pathway in esophageal squamous cell carcinoma.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.